甲巯咪唑对Graves病患者血清FCRL3水平的影响

Effect of Methimazole on Serum FCRL3 Level in Patients with Graves Disease

目的探讨甲巯咪唑对Graves病(GD)患者血清FCRL3水平的影响。方法选取2018年11月~2019年6月我院收治的初诊GD患者30例设为初诊组,经MMI治疗3个月以上GD患者30例设为治疗组,另选取健康体检者30例设为对照组,比较三组实验室检查结果[游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、促甲状腺素(TSH)、抗甲状腺球蛋白抗体(TgAb)、甲状腺过氧化物酶抗体(TPOAb)、促甲状腺素受体抗体(TRAb)、FCRL3水平],并分析FCRL3水平与上述临床检查指标的关系。结果初诊组FT3、FT4、TPOAb、TRAb、TgAb、FCRL3水平高于对照组和治疗组,且TSH水平低于对照组和治疗组,差异有统计学意义(P<0.05);治疗组FCRL3、FT3、FT4、TPOAb、TRAb、TgAb水平高于对照组,TSH水平低于对照组,差异有统计学意义(P<0.05);Spearman相关性分析显示,血清FCRL3与FT3、FT4、TPOAb、TRAb呈正相关(P<0.05),与TSH呈负相关(P<0.05),与TgAb无相关性(P>0.05);多元Logistic回归分析显示,TRAb、FCRL3、FT4是GD的独立危险因素。结论FCRL3可能参与GD的发生发展,甲巯咪唑可能通过抑制FCRL3的过量表达,从而抑制机体甲状腺激素的分泌,起到对GD的治疗及缓解的作用。

Objective To investigate the effect of methimazole on serum FCRL3 level in patients with Graves disease(GD).Methods 30 cases of newly diagnosed GD patients admitted to our hospital from November 2018 to June 2019 were selected as the first diagnosis group,30 cases of GD patients treated with MMI for more than 3 months were set as the treatment group,and 30 healthy patients were selected as the treatment group control group,compare the results of three groups of laboratory tests[free triiodothyronine(FT3),free thyroxine(FT4),thyrotropin(TSH),anti-thyroglobulin antibody(TgAb),thyroid peroxidase Antibody(TPOAb),thyrotropin receptor antibody(TRAb),FCRL3 level],and analyze the relationship between FCRL3 level and the above clinical examination indicators.Results The levels of FT3,FT4,TPOAb,TRAb,TgAb,and FCRL3 in the newly diagnosed group were higher than those in the control group and the treatment group,and the TSH levels were lower than those in the control group and the treatment group,the difference was statistically significant(P<0.05);The levels of FCRL3,FT3,FT4,TPOAb,TRAb,and TgAb in the treatment group were higher than those in the control group,and the TSH levels were lower than that in the control group,the difference was statistically significant(P<0.05);Spearman correlation analysis showed that serum FCRL3 was positively correlated with FT3,FT4,TPOAb,and TRAb(P<0.05),negatively correlated with TSH(P<0.05),and not correlated with TgAb(P>0.05);multiple Logistic regression analysis shows that TRAb,FCRL3 and FT4 are independent risk factors for GD.Conclusion FCRL3 may be involved in the occurrence and development of GD.Methimazole may inhibit the excessive expression of FCRL3,thereby inhibiting the secretion of thyroid hormones in the body,and play a role in the treatment and relief of GD.